In a patient with renal insufficiency and myelodysplastic syndrome with neutropenia, which biologic is best for treating psoriatic arthritis?
No direct evidence for the best biologic for psoriatic arthritis in patients with renal insufficiency and myelodysplastic syndrome with neutropenia. Indirectly, IL-17 inhibitors such as secukinumab appear cost-effective and have a manageable safety profile but careful consideration of comorbidities is advised.
Authors
- Tripdatabase
Publication Details
- Journal
- Zenodo (CERN European Organization for Nuclear Research)
- Published
- 2026-11-03
- DOI
- https://doi.org/10.5281/zenodo.23932390
- Primary Topic
- Spondyloarthritis Studies and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00